Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma
|
February 4, 2022
|
PC3I Authors Ronac Mamtani |
Cancer
|
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy
|
May 13, 2022
|
PC3I Authors Ronac Mamtani |
JAMA Oncology
|
Correction to: Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma
|
June 2, 2022
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research and Clinical Oncology
|
Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice
|
June 7, 2022
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Pharmacoepidemiology and Drug Safety
|
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
|
July 9, 2022
|
PC3I Authors Ronac Mamtani; Ravi Parikh |
JNCI Cancer Spectrum
|
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
|
August 9, 2022
|
PC3I Authors Melina Marmarelis; Ronac Mamtani |
Clinical Lung Cancer
|
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
|
August 10, 2022
|
PC3I Authors Ronac Mamtani |
Journal of the National Comprehensive Cancer Network
|
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors
|
August 29, 2022
|
PC3I Authors Kerry Coughlin; Larry Shulman; Ronac Mamtani |
JAMA Network Open
|
Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden
|
November 13, 2022
|
PC3I Authors Ronac Mamtani; Daniel Lee |
Urologic Oncology
|
Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy
|
December 22, 2022
|
PC3I Authors Daniel Lee; Ronac Mamtani |
BJU International
|
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
|
February 23, 2023
|
PC3I Authors Ronac Mamtani |
BJUI Compass
|
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
|
February 23, 2023
|
PC3I Authors Ramy Sedhom; Ronac Mamtani |
JAMA Oncology
|
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
|
March 2, 2023
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research & Clinical Oncology
|
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90
|
March 19, 2023
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer
|
April 14, 2023
|
PC3I Authors Ronac Mamtani; Ravi Parikh |
JAMA Network Open
|
Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation
|
May 8, 2023
|
PC3I Authors Ronac Mamtani |
Epidemiology
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma
|
September 4, 2023
|
PC3I Authors Ronac Mamtani |
Cancer Investigation
|
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
October 2, 2023
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|